Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023
May 31, 2023 16:00 ET
|
Avadel Pharmaceuticals plc
– 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growing body of evidence demonstrating positive clinical benefit and patient preference of...
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 04, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
-- Received FDA approval for LUMRYZ™ (sodium oxybate), the first and only once-at-bedtime oxybate for treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy – -- FDA...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, May 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of...
Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
May 01, 2023 13:20 ET
|
Avadel Pharmaceuticals plc
- Granted Orphan Drug Exclusivity through May 1, 2030 - -Advanced commercial preparations on track; LUMRYZ product availability expected in early June - - Final approval supported by robust efficacy...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 20, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference
April 10, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, April 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee...
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 30, 2023 07:00 ET
|
Avadel Pharmaceuticals plc
• LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to import LUMRYZ in advance of final approval decision; shortens timeline between potential approval...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
March 29, 2023 21:27 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares
March 29, 2023 21:24 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced...